<DOC>
	<DOCNO>NCT01877005</DOCNO>
	<brief_summary>Phase II study ass efficacy 6 cycle oral JAK1/2 inhibitor ruxolitinib patient advance Hodgkin 's lymphoma curative option available .</brief_summary>
	<brief_title>A Phase II Study Oral JAK1/JAK2 Inhibitor INC424 Adult Patients With Relapsed/Refractory Classical Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion critera : Patients ≥ 18 year classical HL relapse refractory least 1 prior systemic therapy . Patients must relapse highdose therapy ASCT , deem ineligible highdose therapy ASCT ECOG performance status ≤ 3 Measurable nodal disease : 1 cm long transverse diameter clearly measurable least two perpendicular dimension , determine CT scan ( MRI allow CT scan perform ) . Patient follow laboratory value : Absolute neutrophil count ( ANC ) ≥ 1.0 x 10^9/L [ SI unit 1.0 x 10^9/L ] Platelet count ≥ 75 x 10^9/L ] Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Serum bilirubin ≤ 1.5 x ULN ( ≤ 3.0 x ULN , patient Gilbert syndrome ) AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN ≤ 5.0 x ULN transaminase elevation due liver disease involvement Signed write inform consent Life expectancy ≥ 3 month Corrected QT interval ≤ 450 mSec Men woman childbearing potential must agree use adequate method contraception study treatment least 1 week last study drug administration The patient must cover social security system ( inclusion France ) Exclusion criterion : Previous treatment ruxolitinib another JAK inhibitor Contraindication ruxolitinib Patient receive chemotherapy radiotherapy investigational drug within 14 day prior start study drug whose side effect therapy resolve ≤ grade 1 Patient treat allogeneic hematopoietic stem cell transplant currently , receive immunosuppressive therapy within 90 day prior start screen and/or ≥ Grade 2 graft versus host disease ( GvHD ) . Patient prior history another active primary malignancy ≤ 2 year study entry , exception nonmelanoma skin cancer , carcinoma situ uterine cervix Any serious active disease comorbid medical condition , accord investigator 's decision , substantially increase risk associate subject 's participation study . Uncontrolled infectious disease , include active HBV infection define either detection HBs Antigen presence anti HBc antibody without detectable anti HBs antibody . HIV , HCV HTLV serology positivity and/or document infection active hepatitis B Prior history CNS involvement lymphoma Pregnant lactate woman Adult patient unable provide inform consent intellectual impairment , serious medical condition , laboratory abnormality psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multicenter , single arm open label phase II study</keyword>
</DOC>